$ZLAB Completes Enrollment of China Pivotal Trial of Niraparib as SecondLine Maintenance Therapy for Ovarian Cancer in China httpsfinance.yahoo.comnewszailabcompletesenrollmentchina123000316.htmlÂ
$ZLAB Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China https://finance.yahoo.com/news/zai-lab-completes-enrollment-china-123000316.html …
More From BioPortfolio on "$ZLAB Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China https://finance.yahoo.com/news/zai-lab-completes-enrollment-china-123000316.html …"